Member Info for Wiggly

CEO AS said the following;

"It will be a very exciting and genuinely transformational year ahead for Avacta, as we work with our partners to progress through each of the necessary stages to deliver on all of these opportunities and I look forward to keeping the market updated as we hit the major milestones."

I cannot believe we wont delivery as promised during Q4.

Looks like the U.K. vulnerable and elderly will be Pfizer’s guinea pigs

Did anyone from this category take part in the trial? I imagine if they did, they continued to be ultra cautious, thus were not very likely to come into contact with the virus, meaning the stats are somewhat flawed imo.

I think something is up.

News incoming imo

Also - are they all powered by Antibodies?

Do any of these potential competitors have UK Manufacturing infrastructure enabling production of millions per week/month?

Who would Sure Screen be using for manufacture? Their website doesn't really give anything away

Is sure screen in competition?

Promising! Really do believe AVCT and GOV have been working together for some time. The delays with the GOV LFT release have tied with the AVCT delays. A month of so back, Boris spoke about 'The tech' not being quite there but he hoped it was coming soon.

Did he say that?

What were the results?
About 3,000 participants were given the half dose and then a full dose four weeks later, and this regime appeared to provide the most protection or efficacy in the trial - around 90%.

In the larger group of nearly 9,000 volunteers, who were given two full doses also four weeks apart, efficacy was 62%.

AstraZeneca reported these percentages and also said that its vaccine was, on average, 70% effective at preventing Covid-19 illness. The figures left some experts scratching their head.

Prof David Salisbury, immunisation expert and associate fellow of the global health program at the Chatham House think tank, said: "You've taken two studies for which different doses were used and come up with a composite that doesn't represent either of the doses. I think many people are having trouble with that.?

vaccine makers tightly controlled who was enrolled to their trials, their vaccine dosages, the timing of those doses and much more - but they did not monitor participants' other behaviors, like mask-wearing, that affect infection risks.

Trial participants were left to decide for themselves where and how often to wear masks and how to practice social distancing, one told Business Insider.

And these differences in how coronavirus vaccine trial participants behaved could have drastic effects on how likely people who got the vaccine, versus those who got a placebo, were to get infected.

Neither Moderna nor Pfizer gave trial participants instructions on how to behave to try to reduce their infection risks (or not), and didn't log ths behaviors either, unless they suspected someone had caught coronavirus.

It doesn't necessarily mean that the two leading vaccines don't live up to the 90 percent efficacy found by their trials, but it does leave a gap in what we know about how much protection is offered by a shot versus by masking and social distancing.

And it comes as the results of AstraZeneca's trial for the Oxford University-designed shot come under fire after Oxford acknowledged that it was a manufacturing error that led it to try giving participants a half-dose for their first shot - an accidental arm of the trial that proved most effective.

Suspect that their margin operating as a development partner rather than sub-contract manufacturer will be significantly higher - which may mean that they are more willing to allocate their capacity towards production of the AVCT test...

Boris and other senior leaders have spoken many times about British tech/supply. As the roll out of LFTs is so high on the agenda I can only assume that when they speak about British tech/supply they are referring to British produced LFTS.

I think the initial purchase from Innova was necessary due to the AVCT delay.

wyndrum,

"Based on the current info I think Innova are favourites to win it simply because they are already being bought and as others have said buyers tend to stick with suppliers they know."

This does not tie in with the UK desire to have sovereign supply.

wyndrum,

"have no idea where we are after the RNS but I would be surprised if AVCT can start a small scale validation and when that's completed a large scale validation has to get underway and be completed and then get the data into the tender process in time"

The only requirement to participate in the tender is to be passed the futility testing stage. Other than Innova, no other LFT has had large scale validation....

Also - don't forget DOMESTIC supply. Any other likely bidders for this contract going to be British made?

I think AVCT will be participating in the tender. Reasons being;

1. We are clearly very close to having a fit for purpose scalable product ready for mass production (see last RNS)

2. As we are clearly very close, surely discussions have taking place (via partner BBI / RTC and UK GOV) whether UK Gov would support our inclusion (see delayed tender)

3. There is a question mark regarding the Futility testing however, based on comments about moving to clinical validation I believe we are past this stage. Perhaps this was on of the reasons for extending the tender. We obviously have working prototypes that could easily have been assessed over the past weeks.

4. the change to nasal sits well with the tender requirements and the timing of this weeks RNS also ties in very nicely.

5. AS said Q4 would be transformational and the tender and all of the above sits perfectly.

Fingers and toes are crossed.

Agree with comments here that testing likely to remain for a long time. Although the most vulnerable will be vacinated, this is a high contagious and also deadly disease. Many people have underlying health conditions that they are unaware of and will have serious complications of they catch covid.

The airline industry has already confirmed that they will continue with tree sting for many years.

The long term market opp remains for a high performance LFT.

Can Al deliver?

What happened to sona?